Oncolytics Biotech and Oruka Therapeutics see analyst rating shifts and modest stock moves

Oncolytics Biotech Inc. (NASDAQ:ONCY) edged up 0.2% on Thursday, trading as high as $0.7660 and closing at $0.7530 on lower-than‑average volume. Analyst coverage was mixed: Weiss upgraded the stock to a sell rating, HC Wainwright restated a buy, and Wall Street Zen downgraded it to sell. MarketBeat lists a consensus “moderate buy” with an average price target of $8.50. The company reported a quarterly loss of $0.08 per share, missing the $0.05 consensus estimate, and analysts project a full‑year loss of $0.25 per share. Institutional investors added new stakes, including Renaissance Technologies ($608,000) and Citadel Advisors ($535,000).

Oruka Therapeutics Inc. (NASDAQ:ORKA) reached a new 52‑week high of $98.44, ending the session at $97.86 on solid volume. Several analysts issued buy or overweight ratings, with price targets ranging from $120 to $200; the consensus remains a “moderate buy” and an average target of $134.30. The firm posted a quarterly loss of $0.48 per share, beating the $0.52 consensus estimate, while forecasts anticipate a full‑year loss of $2.06 per share. Insider activity included senior vice president Arjun Agarwal selling 9,999 shares at an average price of $84.63, reducing his holding by roughly 40%.